NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer